Call the Office of Patient Recruitment at 800-411-1222 to speak with one of our Information Specialists.
For those who are deaf, hard-of-hearing, or speech impaired, the Federal Relay Service provides free telecommunications relay services (TRS).
Se habla español.
National Cancer Institute Researchers Seeking Patients Diagnosed with Hepatocellular Carcinoma
Are You Diagnosed With Hepatocellular Carcinoma?
Researchers at the National Institutes of Health (NIH) in Bethesda, Maryland are investigating if nivolumab given in combination with tadalafil and vancomycin may help liver tumors to shrink. Nivolumab is an immune therapy treatment agent that helps the immune system effectively fight cancer. Tadalafil is considered to be a cancer treatment sensitizer and vancomycin is an antibiotic that alters the gut bacteria leading to a liver specific immune response by the patient. Current treatment options for patients with liver cancers, including hepatocellular carcinoma (HCC) and advanced liver cancers are limited. This Research study may provide answers for a new treatment that may help patients with hepatocellular carcinoma or metastases to the liver from colorectal or pancreatic cancer for which standard treatment has not been of benefit.
DESIGN OF THE STUDY:
- Physical exam and blood testing
- Scan of the chest, abdomen, and pelvis
- Participants will receive the study drugs in 4-week cycles
- There is no cost for study related medication, tests or procedures
TO BE ELIGIBLE:
- Must be 18 years or older
- Diagnosed with Hepatocellular Carcinoma
- No signs of liver failure
The NIH Clinical Center, America's Research Hospital located in Bethesda, MD Metro red line (Medical Center stop).
For more information:
NIH Clinical Center Office of Patient Recruitment
800-877-8339 TTY / ASCII
Se habla español
Or go online:
Refer to study #19-C-0033
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
NOTE: PDF documents require the free Adobe Reader.
This page last updated on 02/25/2020